MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation

J. Maas, N. de Vries, B. Bloem, J. Kalf (Nijmegen, Netherlands)

Meeting: 2019 International Congress

Abstract Number: 2114

Keywords: Dysarthria, Parkinsonism

Session Information

Date: Wednesday, September 25, 2019

Session Title: Non-Pharmacological Interventions

Session Time: 1:15pm-2:45pm

Location: Les Muses Terrace, Level 3

Objective: To study the effectiveness of personalized speech therapy delivered by telerehabilitation, aiming to improve hypokinetic dysarthria in patients with Parkinson’s disease (PD), regardless of disease stage or living area.

Background: Speech problems in PD have a profound negative impact on social interaction and quality of life. Current speech treatment is overall highly intensive and therefore not suitable for patients in all disease stages. Evidence for these highly intensive programs is growing, but still limited because of small sample sizes or short term follow-up. To address these challenges, we aimed to perform a large-scale study to demonstrate the efficacy of speech therapy in PD on quality of life and speech. To improve compliance of both patients and caregivers, several aspect seem relevant to be taken into account: home-based treatment will make speech therapy more available for patients in all disease stages, the treatment approach should be personalized and real-time feedback may augment exercising and applying better speech.

Method: We will perform a single blind, randomized controlled trial, comparing 8 weeks of speech therapy through telerehabilitation to no intervention using a waiting list design. 215 participants with idiopathic PD in all disease stages with problems in intelligibility are recruited by 14 participating highly specialized speech therapists. All treatments will be personalized, supported by an app that provides real-time feedback during speech and delivered at home via telerehabilitation. All patients will be measured at baseline and after 8 weeks. The experimental group will receive a follow-up measurement after a wash-out period of 24 weeks. The control group will receive deferred treatment after 8 weeks, but no additional follow-up assessments. The primary outcome is quality of life. Secondary outcomes are speech and voice quality, intelligibility, severity of voice and speech complaints, and caregiver burden.

Results: The PERSPECTIVE study has fully started from September 1st 2018 with the inclusion of participants from March 1st 2019 and the study will be finished by August 2021.

Conclusion: This study will be the first to investigate the efficacy of speech therapy in PD in all disease stages on a large scale.

To cite this abstract in AMA style:

J. Maas, N. de Vries, B. Bloem, J. Kalf. Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/design-of-the-perspective-study-personalized-speech-therapy-for-active-conversation/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/design-of-the-perspective-study-personalized-speech-therapy-for-active-conversation/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley